Kurin, Inc. Receives FDA 510(k) Clearance for Its Novel Kurin Lock with Peripheral IV Infusion Set

SAN DIEGO–(BUSINESS WIRE)–Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, has received a second 510(k) clearance (K181895) for its new Kurin® PIV18 peripheral IV configuration with an extension set, which can be used for infusion. “We are pleased to receive clearance from the FDA, the governing body for the medical products and processes we have developed,” said Bob Rogers, CEO of Kurin. “Our Kurin PIV18 product was…

Kurin, Inc. Announces Clinical Results on Kurin® Efficacy from Central Texas Veterans Health Care System

SAN DIEGO–(BUSINESS WIRE)–Kurin, Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that the Temple VA Hospital in Temple, TX, presented their findings comparing results of Kurin and Magnolia Medical’s Steripath at the recent Southwest Association of Clinical Microbiology. They are the first hospital to report on results comparing Kurin®, a passive low-volume diversion technology to Steripath®, a mechanical diversion device. They concluded that both…

Spinal Singularity Awarded Phase II SBIR Grant From NIH

SAN CLEMENTE, Calif., Oct. 4, 2018 /PRNewswire/ — Spinal Singularity announced that the company was awarded a Phase II SBIR grant from the National Institute of Health (NIH). The grant will provide approximately $1.5 Million in non-dilutive funding to continue clinical development of the Connected Catheter 2P (C2P). Bill Colone, CEO of Spinal Singularity, said, “We are honored to receive this award from the NIH. This funding will finance a…

Spinal Singularity Treats First Patient

SAN CLEMENTE, Calif., March 8, 2018 /PRNewswire/ — Spinal Singularity announced that the first patient has been treated with the Connected Catheter, an innovative, smart catheter system designed for adult males with Chronic Urinary Retention and/or Neurogenic Lower Urinary Tract Dysfunction (NLUTD). The Clinical Feasibility Study is being led by Dr. Ernest Agatstein, MD, an expert Urologist and co-founder of West Coast Urology. Dr. Agatstein has served as a Scientific…